Zimmer Biomet (NYSE:ZBH) Issues FY 2021 Earnings Guidance
Zimmer Biomet (NYSE:ZBH) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided EPS guidance of 7.600-8.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.720. The company issued revenue guidance of $8.01 billion-$8.22 billion, compared to the consensus revenue estimate of $7.97 billion.Zimmer Biomet also updated its FY21 guidance to $7.60-$8.00 EPS.
Shares of NYSE ZBH traded down $5.01 during midday trading on Tuesday, hitting $172.93. 1,754,512 shares of the company’s stock were exchanged, compared to its average volume of 1,214,433. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.18 and a quick ratio of 1.02. The stock’s 50 day moving average price is $167.30 and its 200-day moving average price is $156.15. The firm has a market cap of $36.02 billion, a P/E ratio of 1,080.88, a PEG ratio of 4.32 and a beta of 1.34. Zimmer Biomet has a twelve month low of $108.78 and a twelve month high of $180.36.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, May 4th. The medical equipment provider reported $1.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.20. The business had revenue of $1.85 billion during the quarter, compared to the consensus estimate of $1.75 billion. Zimmer Biomet had a return on equity of 10.07% and a net margin of 0.52%. The business’s revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.70 earnings per share. On average, analysts expect that Zimmer Biomet will post 4.8 EPS for the current fiscal year.
A number of equities research analysts have weighed in on the company. SVB Leerink upped their target price on Zimmer Biomet from $185.00 to $190.00 and gave the stock an outperform rating in a research report on Monday, February 8th. Piper Sandler upped their target price on Zimmer Biomet from $185.00 to $195.00 and gave the stock an overweight rating in a research report on Friday, February 5th. Evercore ISI upgraded Zimmer Biomet from an in-line rating to an outperform rating and set a $175.00 target price for the company in a research report on Monday, January 4th. Needham & Company LLC upped their target price on Zimmer Biomet from $185.00 to $192.00 and gave the stock a strong-buy rating in a research report on Friday, February 5th. Finally, JMP Securities upped their target price on Zimmer Biomet from $165.00 to $180.00 and gave the stock an outperform rating in a research report on Wednesday, January 27th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $167.83.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.
Featured Story: What does an equal weight rating mean?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.